How to Finance a Speech Therapy Practice Acquisition

From SBA 7(a) loans to equity rollovers, understand the capital structures buyers and sellers use to close speech-language pathology deals in the $1M–$5M revenue range.

Find Speech Therapy Practice Deals SBA Calculator →

Speech therapy practices are among the most SBA-eligible healthcare businesses due to stable cash flows, defensible referral networks, and recession-resistant demand. Buyers typically combine SBA debt, seller notes, and equity contributions to acquire practices valued at 3.5–6x EBITDA. Understanding your financing options is critical given SLP workforce costs, payer mix complexity, and the clinical transition risks unique to this industry.

Financing Options for Speech Therapy Practice Acquisitions

SBA 7(a) Loan

$500K–$5MPrime + 2.75%–3.5% (variable); currently ~10.5%–11.5%

The most common financing tool for speech therapy acquisitions. Covers up to 90% of the purchase price including goodwill, working capital, and equipment. Requires lender approval of healthcare practice cash flow and payer mix sustainability.

Pros

Low equity injection requirement (10–20%) preserving buyer liquidity for post-close operations and SLP hiring
Goodwill financing available — critical for therapy practices where intangible value dominates the purchase price
10-year repayment term keeps monthly debt service manageable against practice EBITDA

Cons

×Lenders scrutinize Medicaid concentration and payer mix — high Medicaid exposure may trigger loan conditions or reduced proceeds
×Owner-dependent practices where the seller performs 40%+ of billable hours face heightened lender scrutiny and possible deal structure requirements
×Lengthy underwriting process (60–90 days) requiring clean accrual financials, credentialing records, and compliance documentation

Seller Financing (Seller Note)

$75K–$600K6%–8% fixed; 2-year standby period if SBA is senior lender

The seller extends a note for 5–15% of the purchase price, typically subordinated to the SBA loan. Common in SLP practice deals to bridge valuation gaps, fund earnout mechanics, or retain seller alignment through clinical transition.

Pros

Signals seller confidence in practice performance and eases SBA lender concerns about post-close revenue retention
Defers a portion of purchase price, reducing buyer equity requirement and improving day-one cash flow
Flexible structuring allows tie-in to clinician retention milestones or referral source continuity benchmarks

Cons

×SBA standby requirements mean seller receives no payments for up to 24 months, which some retiring SLPs find unacceptable
×Seller note increases total debt burden — must be modeled carefully against DSCR thresholds with SBA senior debt in place
×Negotiating note terms can stall deals when seller needs full liquidity at close for retirement or estate planning purposes

Equity Rollover / Partial Seller Equity Retention

10–20% of enterprise value retainedN/A — equity instrument; return realized at next liquidity event

Seller retains 10–20% equity stake post-close, often paired with a clinical director or referral development role for 12–24 months. Common in PE-backed roll-up acquisitions of established SLP practices with strong school or physician referral networks.

Pros

Aligns seller incentives with post-close performance, reducing risk of referral source attrition or SLP staff departures during transition
Reduces upfront cash needed from buyer or PE sponsor while giving seller participation in future value creation
Supports a structured clinical transition — seller remains engaged with school district contracts and physician relationships through rollover period

Cons

×Seller retains ongoing liability exposure and must remain involved operationally, which conflicts with full-exit retirement goals
×Minority equity stake may create governance friction if buyer and seller disagree on clinical staffing or expansion decisions post-close
×Valuation of rolled equity at exit depends on platform performance — seller bears downside risk if roll-up strategy underperforms

Sample Capital Stack

$2,400,000 (representing a 5x multiple on $480,000 EBITDA for a 3-SLP practice with $2M revenue and diversified payer mix)

Purchase Price

~$23,200/month on SBA note at 11% over 10 years; seller note payments deferred during standby period

Monthly Service

Approximately 1.35x DSCR based on $480,000 EBITDA against ~$278,400 annual debt service — within SBA lender comfort range of 1.25x minimum

DSCR

SBA 7(a) Loan: $2,040,000 (85%) | Seller Note on 24-month standby: $120,000 (5%) | Buyer Equity Injection: $240,000 (10%)

Model your own deal structure →

Lender Tips for Speech Therapy Practice Acquisitions

1Target SBA lenders with healthcare or therapy practice loan portfolios — they understand payer mix normalization, SLP salary add-backs, and goodwill valuation without requiring excessive documentation overrides.
2Prepare a payer mix analysis showing insurance, private pay, and Medicaid as percentages of revenue. Lenders will stress-test Medicaid reimbursement rate cuts — practices above 40% Medicaid may need additional equity or a larger seller note.
3Document the seller's clinical role reduction plan pre-close. Lenders want evidence that at least 3 employed SLPs hold independent patient relationships, minimizing key-person revenue concentration risk that could impair loan repayment.
4Order a billing and coding compliance review before submitting your loan package. Unresolved insurance audit exposure or CMS overpayment risk is a deal-stopper — clean documentation accelerates underwriting and strengthens your credit narrative.

Frequently Asked Questions

Can I use an SBA loan to buy a speech therapy practice if I'm not a licensed SLP?

Yes. SBA 7(a) loans are available to non-clinician buyers acquiring speech therapy practices, provided you hire qualified SLP leadership. Lenders will scrutinize your healthcare management experience and post-close staffing plan to ensure continuity of licensed clinical operations.

How does Medicaid revenue concentration affect my ability to get SBA financing?

Practices with Medicaid above 40–50% of revenue face lender scrutiny due to reimbursement rate volatility and state policy risk. Lenders may require larger equity injections, a seller note buffer, or evidence of diversification efforts before approving full SBA proceeds.

What EBITDA margins do SBA lenders expect from a speech therapy practice to approve financing?

Most SBA lenders target a 1.25x minimum DSCR, which typically requires EBITDA margins of 18–25% after owner compensation normalization. Practices with margins below 15% may require restructured deal terms or a larger buyer equity contribution to satisfy debt service coverage.

Is a seller note required in most speech therapy practice acquisitions?

Not always required, but strongly encouraged by SBA lenders. A 5–10% seller note signals the seller's confidence in post-close performance and helps bridge valuation gaps — particularly when referral source durability or SLP retention post-acquisition is uncertain.

More Speech Therapy Practice Guides

Buy a Speech Therapy Practice Business →Valuation Guide →SBA Loan Guide →Deal Structure →Common Mistakes →SBA Calculator →Deal Structure Builder →

Ready to finance your Speech Therapy Practice acquisition?

DealFlow OS surfaces acquisition targets and helps you structure the deal. Free to join.

Start finding deals — free

No credit card required